102
Participants
Start Date
November 26, 2020
Primary Completion Date
March 30, 2023
Study Completion Date
November 25, 2024
Durvalumab
All patients will receive 1500 mg durvalumab via IV infusion q4w for up to a maximum of 12 months.
Research Site, Barcelona
Research Site, Castellon
Research Site, Marseille
Research Site, A Coruña
Research Site, Genova
Research Site, Monza
Research Site, Brescia
Research Site, Pavia
Research Site, Madrid
Research Site, Nîmes
Research Site, Pamplona
Research Site, Oviedo
Research Site, Tampa
Research Site, Montpellier
Research Site, Negrar
Research Site, Modena
Research Site, Meldola
Research Site, Royal Oak
Research Site, Ravenna
Research Site, Florence
Research Site, Pisa
Research Site, Rouen
Research Site, Tucson
Research Site, Limoges
Research Site, Messina
Research Site, Saint Petersburg
Research Site, Saint Petersburg
Research Site, Ufa
Research Site, Roma
Research Site, Bialystok
Research Site, Gdansk
Research Site, Olsztyn
Research Site, Szczecin
Research Site, Warsaw
Research Site, Sabadell(Barcelona)
Lead Sponsor
AstraZeneca
INDUSTRY